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EpCAM expression varies significantly and
is differentially associated with prognosis
in the luminal B HER2 þ , basal-like, and
HER2 intrinsic subtypes of breast cancer
S D Soysal1,2,7, S Muenst*,2,3,7, T Barbie2, T Fleming2, F Gao4, G Spizzo5,6, D Oertli1, C T Viehl1,
E C Obermann3 and W E Gillanders2
1

Department of Surgery, University Hospital Basel, Spitalstrasse 21, Basel 4031, Switzerland; 2Department of Surgery, Washington
University School of Medicine, 660 South Euclid Avenue, St. Louis, MO 63110, USA; 3Institute of Pathology, University Hospital
Basel, Schoenbeinstrasse 40, Basel 4031, Switzerland; 4Division of Biostatistics, Washington University School of Medicine, 660
South Euclid Avenue, St. Louis, MO 63110, USA; 5Tyrolean Cancer Research Institute, Innrain 66, Innsbruck 6020, Austria and
6
Division of Haematology and Oncology, Franz Tappeiner Hospital, Rossinistrasse 5, Merano 39012, Italy
Background: Epithelial cell adhesion molecule (EpCAM) is frequently expressed in breast cancer, and its expression has been
associated with poor prognosis. Breast cancer can be subdivided into intrinsic subtypes, differing in prognosis and response to
therapy.
Methods: To investigate the association between EpCAM expression and prognosis in the intrinsic subtypes of breast cancer, we
performed immunohistochemical studies on a tissue microarray encompassing a total of 1365 breast cancers with detailed
clinicopathological annotation and outcomes data.
Results: We observed EpCAM expression in 660 out of 1365 (48%) cases. EpCAM expression varied significantly in the different
intrinsic subtypes. In univariate analyses of all cases, EpCAM expression was associated with a significantly worse overall survival. In
the intrinsic subtypes, EpCAM expression was associated with an unfavourable prognosis in the basal-like and luminal B HER2 þ
subtypes but associated with a favourable prognosis in the HER2 subtype. Consistently, specific ablation of EpCAM resulted in
increased cell viability in the breast cancer cell line SKBR3 (ER  , PR  , and HER2 þ ) but decreased viability in the breast cancer cell
line MDA-MB-231 (ER  , PR  , and HER2  ).
Conclusion: The differential association of EpCAM expression with prognosis in intrinsic subtypes has important implications for
the development of EpCAM-targeted therapies in breast cancer.

The epithelial cell adhesion molecule (EpCAM, also designated
TACSTD1, CD326) is a type I transmembrane protein of 314
amino acids that is localised to the basolateral membrane in the
majority of normal epithelial tissues. The functional role of
EpCAM in cell adhesion was the focus of early studies, and

EpCAM has been demonstrated to be a calcium-independent
homophilic cell adhesion molecule (Litvinov et al, 1994). Recent
studies have also demonstrated a role for EpCAM in cell signalling
and carcinogenesis (Munz et al, 2004; Osta et al, 2004; Maetzel
et al, 2009). EpCAM is perhaps best known for the fact that it is
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expressed in the majority of human epithelial cancers, including
colorectal, breast, gastric, prostate, ovarian, and lung cancer
(Spizzo et al, 2004; Went et al, 2004). EpCAM was the first
human tumour-associated antigen to be identified with monoclonal antibodies (Herlyn et al, 1979) and was the first target of
monoclonal antibody therapy in humans (Sears et al, 1982).
EpCAM expression has also been used to enrich circulating
tumour cells before microscopic evaluation in the only FDAapproved assay for detection of circulating tumour cells in breast
cancer (Cristofanilli et al, 2004). Finally, EpCAM-targeted
therapies remain under active investigation, and a recent report
highlighted at least seven different molecular therapies targeting
EpCAM in various cancer types, including breast, gastric, ovarian,
and lung cancer (Baeuerle and Gires, 2007). Particular effort is
being made for breast cancer patients, where EpCAM expression
appears to predict response to EpCAM-targeting antibodies
(Schmidt et al, 2010; Schmidt et al, 2012).
EpCAM expression in primary cancer specimens has been
associated with a favourable prognosis in some cancer types and an
unfavourable prognosis in other cancer types. For instance,
EpCAM expression in primary breast and ovarian cancers as
measured by immunohistochemistry is associated with poor overall
survival (OS; Spizzo et al, 2002; Spizzo et al, 2004; Spizzo et al,
2006; Schmidt et al, 2008), while EpCAM expression in colorectal
and gastric cancer is associated with more favourable prognosis
(Songun et al, 2005; Went et al, 2006). All of these studies were
performed using standardised assay conditions and several used
tissue microarrays (TMAs); taken together, these studies include
specimens from over 6000 cancer patients. This differential
association between EpCAM expression and prognosis is paralleled
in functional studies of EpCAM biology performed both in vitro
and in vivo. Loss-of-function analyses using RNA interference
suggest that EpCAM expression is associated with increased
invasion in breast cancer (Osta et al, 2004; Sankpal et al, 2009a, b,
2011), and gain-of-function analyses in colorectal and lung cancer
suggest that EpCAM expression is associated with decreased cancer
invasion (Basak et al, 1998; Tai et al, 2007). Moreover, in breast
cancer cell lines, the impact of EpCAM expression on proliferation
has been recently shown to depend on the epithelial and
mesenchymal phenotype of these cells (Martowicz et al, 2012).
Taken together, these studies suggest that the impact of EpCAM
expression on cancer biology may be context-dependent (reviewed
in van der Gun et al, 2010).
Breast cancer is a heterogeneous disease. Recent advances in
molecular biology, including the development of sophisticated
techniques for gene expression profiling, have established a new
taxonomy of breast cancer, defining the breast cancer intrinsic
subtypes (Perou et al, 2000). This new taxonomy has had a
profound impact on the clinical management of breast cancer, as
the intrinsic subtypes differ markedly in prognosis and response to
therapy. As gene expression profiling data are not always available,
a recent international consensus conference defined an approximation, using immunohistochemical expression of oestrogen
receptor (ER) and progesterone receptor (PR), overexpression,
and/or amplification of the human epidermal growth factor
receptor 2 (HER2) and Ki67 labelling index to approximate the
breast cancer intrinsic subtypes (Goldhirsch et al, 2011).
Although EpCAM expression is associated with poor prognosis
in breast cancer, the impact of EpCAM expression on prognosis in
the breast cancer intrinsic subtypes remains to be defined. As noted
above, this is an important question, as the breast cancer intrinsic
subtypes have distinct biology, and there is strong evidence
suggesting that the impact of EpCAM in cancer is contextdependent. To definitively address this question, we performed
immunohistochemical studies on a breast cancer TMA encompassing a total of 1365 breast cancer cases with detailed clinical
annotation and outcomes data. A better understanding of the
www.bjcancer.com | DOI:10.1038/bjc.2013.80
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Table 1. Basic demographic data for 1365 evaluable breast cancer cases

Mean tumour size (mm)

31.0

Mean age at diagnosis (years)

63.5

Tumour stage
Number (n)

%

pT1

364

26.7

pT2

728

53.4

pT3

104

7.6

pT4

169

12.3

pN0

701

51.5

pN1

529

38.8

pN2

132

9.7

1

318

23.3

2

551

40.4

3

496

36.3

Invasive ductal

977

71.6

Invasive lobular

187

13.7

Mucinous

38

2.8

Apocrine

17

1.2

Cribriform

41

3.0

Papillary

18

1.3

Lymph node involvement

Tumour grade

Histological subtype

Medullary

43

3.2

Other

43

3.2

213

15.6

and/or PR , HER2 ,

673

49.3

Luminal B (HER2-positive) (ER þ and/or PR þ , HER2 þ )

154

11.3

Intrinsic subtype
Luminal A (ER þ and/or PR þ , HER2  , Ki-67o14%)
Luminal B (HER2-negative) ER
Ki-67X14%)

HER2 type (ER





þ

þ

þ

or PR , HER2 )

Basal-like (ER  , PR  , HER2  )



111

8.2

213

15.6

Abbreviations: ER ¼ oestrogen receptor; HER2 ¼ human epidermal growth factor receptor
2; pr ¼ progesterone receptor.

relationship between EpCAM expression and prognosis in
the breast cancer intrinsic subtypes has important implications
for the design and successful application of molecular therapies
targeting EpCAM in breast cancer.

MATERIALS AND METHODS

Tissue microarray. We used a TMA encompassing a total of 2020
breast cancer tissue punches from 1579 formalin-fixed and
paraffin-embedded tumour samples. These samples were collected
from patients diagnosed with primary breast cancer between 1985
and 2007 at the University of Basel and the Viollier Institute in
Basel, Switzerland. Of these 2020 tissue punches, a total of 1365
cases were evaluable for our study. The tissue samples were
1481
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Table 2. Association between EpCAM expression and clinicopathological
parameters

Clinicopathological parameter

EpCAMpositive

EpCAMnegative

P value

Mean tumour size (mm)

34.2

27.8

o0.0001

Mean age age at diagnosis (years)

63.7

63.3

0.6220
o0.0001

Tumour stage
pT1

132

36.3

232

63.7

pT2

366

50.3

362

49.7

pT3

65

62.5

39

37.5

pT4

97

57.4

72

42.6

pN0

329

46.9

372

53.1

pN1

248

46.9

281

53.1

pN2

83

62.9

49

37.1

1

99

31.1

219

68.9

2

234

42.5

317

57.5

3

327

65.9

169

34.1

ER þ

439

42.9

583

57.1

ER 

221

65.2

118

34.8

HER2 þ

144

54.3

121

45.7

HER2 

516

46.9

584

53.1

Ki67 þ

593

55.4

477

44.6

Ki67 

66

23.0

221

77.0

Lymph node involvement

0.0023

o0.0001

Tumour grade

o0.0001

Oestrogen receptor

HER2

0.0298

o0.0001

Ki67

Figure 1. Representative photographs of EpCAM expression in breast
cancer. (A) Strong membranous expression in 100% of tumour cells.
(B) Negative expression on tumour cells with positive expression in
normal mammary glands as an internal positive control. Original
magnification  400. A full color version of this figure is available at the
British Journal of Cancer online.

Abbreviations: EpCAM ¼ epithelial cell adhesion molecule; ER ¼ oestrogen receptor;
HER2 ¼ human epidermal growth factor receptor 2; PR ¼ progesterone receptor.

Table 3. Association between EpCAM expression and histological
subtype

brought into a TMA format as previously described (Bubendorf
et al, 2001). Briefly, 0.6-mm tissue cylinders were punched out of
donor tumour tissue blocks and transferred into a recipient
paraffin block using a semi-automated tissue arrayer. Each TMA
contained a number of tumour punches ranging from 159 to 522.
Histopathological data were obtained from the original pathology
reports, and patient outcomes data were obtained from the Cancer
Registry of Basel or from the patient’s attending physician.
Retrieval of tissue and clinical data was performed in accordance
with the regulations of the local institutional review boards, with
specific attention to ethical standards and patient confidentiality.
Immunohistochemistry. Immunohistochemical staining of the
TMA was performed as described previously (Tapia et al, 2011).
For EpCAM immunohistochemistry, 4 mm sections of the TMA
blocks were incubated overnight with a primary anti-EpCAM
monoclonal antibody (1 : 800; clone VU-1D9, Novocastra,
Newcastle, UK) after heat-induced antigen retrieval. Standard
ABC-technique (ABC-Elite-Kit, Vector Laboratories, Burlingham,
CA, USA) was used for immunostaining, and diaminobenzidine
was used as chromogen. Counterstaining was performed with
hematoxylin solution. The staining intensity of ER, PR, and HER2
was scored as previously described (Tapia et al, 2011). EpCAM
1482

EpCAMpositive
Histological subtype

EpCAMnegative

n

%

n

%

496

50.8

481

49.2

Lobular

48

25.7

139

74.3

Mucinous

20

52.6

18

47.4

Apocrine

13

76.5

4

23.5

Cribiform

12

29.3

29

70.7

Papillary

12

66.7

6

33.3

Medullary

36

83.7

7

16.3

Other

23

53.5

20

46.5

Invasive ductal

P-value
o0.0001

Abbreviation: EpCAM ¼ epithelial cell adhesion molecule.

expression was quantified using the modified Histo-score
(H-score) (McCarty et al, 1985), with a range of possible scores
from 0–300. Frequency and staining intensity of EpCAM on
tumour cells were analysed, and EpCAM expression was
www.bjcancer.com | DOI:10.1038/bjc.2013.80
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Table 4. Association between EpCAM expression and breast cancer
intrinsic subtype

EpCAMpositive
Intrinsic subtype

n

EpCAMnegative

%

n

%

48

22.5

165

77.5

332

49.3

341

50.7

Luminal B (HER2-positive) (ER þ
and/or PR þ , HER2 þ )

63

40.9

91

59.1

HER2 type (ER  , PR  , HER2 þ )

81

73.0

30

27.0

136

63.8

77

36.2

Luminal A (ER þ and/or PR þ ,
HER2  , Ki-67o14%)
Luminal B (HER2-negative) (ER þ
and/or PR þ , HER2  , Ki-67X14%)







Basal-like (ER , PR , HER2 )

P-value
o0.0001

Abbreviations: EpCAM ¼ epithelial cell adhesion molecule; ER ¼ oestrogen receptor;
HER2 ¼ human epidermal growth factor receptor 2; PR ¼ progesterone receptor.

Table 5. Univariate analyses for all cases, and by intrinsic subtype, for the
effect of EpCAM expression on overall survival

EpCAM expression, all cases
EpCAM-positive

Hazard ratio (95% CI) P-value
1.402 (1.178–1.668)

0.0001

EpCAM expression, by intrinsic subtype
Luminal A

1.487 (0.817–2.707)

0.1937

Luminal B (HER2  )

1.208 (0.936–1.560)

0.1464

Luminal B (HER2 þ )

2.400 (1.451–3.971)

0.0006

HER2 type

0.374 (0.217–0.644)

0.0004

Basal-like

1.634 (1.070–2.497)

0.0231

Abbreviations: EpCAM ¼ epithelial cell adhesion molecule; CI ¼ confidence interval;
HER2 ¼ human epidermal growth factor receptor 2.

dichotomised into two groups according to the frequency
distributions of the H-scores, using a cut-off score of X100
(H-score 0–99 ¼ negative/low expression and 100–300 ¼ positive
expression).
Statistical analysis. The distribution of patient and clinical
characteristics between EpCAM-positive and EpCAM-negative
tumours was compared using the Chi-square test, Wilcoxon’s rank
sum test, or two-sample t-test, as appropriate. OS was defined as
the time from the first operation to death due to any cause.
Survivors were censored at the date of last contact. Survival curves
by EpCAM status were estimated using the Kaplan–Meier productlimit method and compared by log-rank test. Univariate Cox
proportional hazard models were fit to identify factors significantly
related to OS. To assess whether EpCAM was an independent
predictor of survival, a multivariate Cox model was constructed to
adjust other patient/clinical characteristics that were significant
in the univariate analyses. Two-way interaction terms between
EpCAM and other factors in the multivariate Cox model were also
assessed. All analyses were two-sided and significance was set at a
P-value of 0.05. Statistical analyses were performed using SAS
(SAS Institutes, Cary, NC, USA).
Cell culture. All breast cancer cell lines were obtained from
the American Type Culture Collection (Rockville, MD, USA).
MCF-10A cells were grown in DMEM/F12 medium supplemented
with 5% donor horse serum, 20 ng ml  1 epidermal growth factor,
www.bjcancer.com | DOI:10.1038/bjc.2013.80

10 mg ml  1 insulin, 100 mg ml  1 hydrocortisone, and 1 ng ml  1
cholera toxin. MDA-MB-231 and SKBR3 cells were grown in
DMEM medium supplemented with 10% FBS.
Antibodies and western blot analysis. Western blotting was
performed by standard procedures. Cell lysates were harvested
with RIPA buffer (50 mM Tris HCl pH 7.4, 150 mM NaCl,
2 mM EDTA, 1% NP40, 0.1% SDS, 0.5% sodium deoxycholate,
1  complete protease inhibitors (Roche, Basel, Switzerland), and
phosphatase inhibitors, including sodium orthovanadate (Sigma,
St. Louis, MO, USA) and sodium fluoride (Sigma). Protein
concentration was measured using the BCA protein assay (Thermo
Scientific, Rockford, IL, USA). Equal loading of each sample of
protein (20 mg) was then subjected to SDS–PAGE (NuPAGE,
Invitrogen, Carlsbad, CA, USA) and transferred by electrophoresis
to a PVDF membrane. Antibodies against EpCAM C-10 (Santa
Cruz, Dallas, TX, USA) and Actin C-4 (Santa Cruz) were used at
ratios of 1 : 1000 and 1 : 5000, respectively, and detection was
performed with HRP-conjugated antisera and chemiluminescence
(Thermo Scientific, Rockford, IL, USA).
Lentiviral shRNA production and infections. Lentiviral vectors
encoding shRNAs specific for EpCAM as well as control GFP
sequences are part of The RNAi Consortium shRNA Library
(http://www.broadinstitute.org/rnai/trc). Sequences are as follows:
for shRNA EpCAM, 50 GCAAATGGACACAAATTACAA30 ; and
for shRNA GFP, 50 ACAACAGCCACAACGTCTATA30 . Lentivirus
was produced by transfection of 293T cells with vectors encoding
gene-specific shRNAs (1 mg) together with the packaging plasmids
encoding D8.9 and VSV-G using Fugene 6 (Roche). Culture
supernatants containing lentivirus were collected 48 and 72 h post
transfection. Virus was pooled and stored at  80 1C. Cells were
infected using a 1 : 11 dilution of virus in polybrene-containing
media. Following centrifugation at 1000 g for 15 min, all breast
cancer cell lines were selected in puromycin (1 mg ml  1) starting
24 h post infection. Viability assays were conducted 10 days
post infection using crystal violet. Protein lysates were harvested
72 h following shRNA expression to evaluate gene suppression.
Crystal violet cell proliferation assay. Cell proliferation assays
were performed in six-well plates. Cells were plated to achieve 50%
cell density on day of lentiviral infection. Puromycin selection 24 h
post infection was performed. On day 3 post infection, cells were
re-plated onto 60-mm dishes. On day 10, plates were stained with
crystal violet (crystal violet 0.2%, ethanol 2%) and photographed.
The crystal violet stain was then solubilised in 1% SDS solution
with incubation on a shaker for 1 h at room temperature. Optical
density was measured at 595 nm. Cell proliferation effects for SKBR-3 after exposure to EpCAM shRNA and GFP shRNA were
analysed as percentages. The solubilised dye from the EpCAM
shRNA sample was read at 100% and then serially diluted to 75%,
50%, and 25% to generate a crystal violet curve to extrapolate the
percentage for the GFP shRNA sample. Data presented are
representative of three independent experiments.
RESULTS

The expression of EpCAM could be evaluated in 1365 cases in this
cohort. Basic demographic information for the 1365 evaluable
cases is presented in Table 1. The mean age at diagnosis was
63.5 years (range 27–101 years), and the mean follow-up time was
80.8 months (range 1–263 months). Expression of EpCAM
was confined to the membrane of breast cancer cells in all the
cases (Figure 1). EpCAM expression was defined using the
H-score, a score integrating the intensity of EpCAM staining,
and the percentage of breast cancer cells expressing EpCAM. With
an H-score threshold of X100, a total of 660 breast cancers
1483
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Lum A
1.0

0.8

0.8

Overall survival

Overall survival

All
1.0

0.6
0.4
EpCAM-negative
EpCAM-positive

0.2

P <0.001

0.0

0 12

0.6
0.4
EpCAM-negative
EpCAM-positive

0.2

P <0.194

0.0

36
60
84
108
Time to death (months)

0

48
24
72
96
Time to death (months)
Lum B, HER2+

0.8

0.8

0.6
0.4
EpCAM-negative
EpCAM-positive

P <0.146

0.0
0

0.6
0.4
EpCAM-negative
EpCAM-positive

P <0.001
0

24
72
96
48
Time to death (months)

48
24
72
96
Time to death (months)

0.8
0.6
0.4
EpCAM-negative
EpCAM-positive

P <0.023

0.0
120

120

Basal-like

0.2

P <0.001
0

EpCAM-negative
EpCAM-positive

0.2

1.0

0.8

0.0

0.4

120

HER2+

0.2

0.6

0.0

24
48
72
96
Time to death (months)

1.0
Overall survival

Overall survival

1.0

Overall survival

Overall survival

Lum B, HER2–
1.0

0.2

120

0

24
48
72
96
Time to death (months)

120

Figure 2. Kaplan–Meier survival curves. (A) Kaplan–Meier survival curve for overall survival depending on EpCAM overexpression (univariate
analysis). (B–F) Kaplan–Meier survival curves for overall survival depending on EpCAM overexpression for indivdual intrinsic breast cancer
subtypes.

(48.3%) expressed EpCAM. Consistent with previous studies,
EpCAM expression was significantly associated with greater
tumour size, lymph node involvement, tumour stage, and tumour
grade (Table 2; Gastl et al, 2000; Schmidt et al, 2008; Agboola et al,
2011; Spizzo et al, 2011). EpCAM expression was significantly
higher in ER-negative (ER  ) cases (EpCAM expression 65.1% in
ER  cancers vs 42.9% in ER þ cancers, Po0.0001, Table 2) and in
HER2 þ cases (EpCAM expression 54.3% in HER2 þ cancers vs
46.9% in HER2  cancers, P ¼ 0.0298, Table 2). EpCAM expression was also significantly associated with histological subtype
(Po0.0001); EpCAM expression was higher in the invasive ductal
(51%) and medullary (84%) histological types and lower
in the invasive lobular (26%) and cribiform (29%) subtypes
(Table 3). EpCAM expression varied significantly between the
intrinsic subtypes of breast cancer, as defined by the St. Gallen
Consensus Conference criteria (Goldhirsch et al, 2011). EpCAM
overexpression was highest in the basal-like (64%) and HER2
(73%) subtypes and lowest in the luminal A subtype (23%,
Po0.0001; Table 4). Furthermore, EpCAM expression was highly
correlated with the expression of Ki-67 in all of the intrinsic
subtypes except for luminal A (data not shown).
In univariate survival analyses, we could demonstrate that breast
cancer cases with EpCAM expression had a significantly worse OS
(hazard ratio (HR) ¼ 1.402, P ¼ 0.0001; Table 5 and Figure 2).
In univariate analyses of the breast cancer intrinsic subtypes,
1484

EpCAM expression was associated with significantly decreased OS
in the luminal B HER2 þ subtype (HR ¼ 2.4, P ¼ 0.0006) and the
basal-like subtype (HR ¼ 1.634, P ¼ 0.023; Table 5 and Figure 2).
The luminal A and the luminal B HER2  subtypes also showed a
trend towards decreased OS with EpCAM expression (Table 5 and
Figure 2), but this was not statistically significant. Of particular
interest, EpCAM expression was significantly associated with
improved OS in the HER2 subtype (HR ¼ 0.374, P ¼ 0.0004;
Table 5 and Figure 2). In multivariate analysis, after adjusting
for age, tumour size, lymph node involvement, tumour grade, and
intrinsic subtype, EpCAM expression remained significantly
associated with improved OS in the HER2 subtype (HR ¼ 0.329,
Po0.0001) and showed a trend toward decreased OS in the
luminal B HER2 þ subtype (HR ¼ 1.546, P ¼ 0.094) and the basallike subtype (HR ¼ 1.437, P ¼ 0.096; Table 6).
Previously, we demonstrated that specific ablation of EpCAM
significantly decreased proliferation of the basal-like breast cancer
cell line MDA-MB-231, with minimal impact on proliferation of
the breast epithelial cell line MCF10A. Given the differential
association between EpCAM and prognosis in the HER2 and basallike intrinsic subtypes of breast cancer, we sought to evaluate the
impact of EpCAM expression on proliferation in representative
breast cancer cell lines in vitro. We specifically ablated EpCAM
expression in the MCF10A, MDA-MB-231, and SKBR3 (ER  /
PR  /HER2 þ ) cell lines (Figure 3). Of note, we not only confirmed
www.bjcancer.com | DOI:10.1038/bjc.2013.80
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Table 6. Multivariate analysis for the effect of clinicopathological
parameters and EpCAM expression on overall survival

Clinicopathological parameter
Age (per 1 year )

Hazard ratio
(95% CI)

P-value

1.037 (1.029–1.044)

o0.0001

Tumour stage
pT1 (reference)

1

pT2

1.603 (1.226–2.097)

0.0006

pT3

2.089 (1.437–3.037)

0.0001

pT4

2.208 (1.581–3.083)

o0.0001

Lymph node involvement
pN1 (reference)

1

pN1

1.427 (1.168–1.745)

0.0005

pN2

2.782 (2.103–3.680)

o0.0001

Tumour grade
BRE grade 1 (reference)

1

Grade 2

1.631 (1.230–3.454)

0.0006

Grade 3

2.571 (1.914–3.454)

o0.0001

Intrinsic subtype
Luminal A (reference)
Luminal B (HER2  )

1
1.081 (0.792–1.475)

0.6237

Luminal B (HER2 )

1.263 (0.864–1.848)

0.2283

HER2 type

1.193 (0.784–1.815)

0.4097

Basal-like

2.031 (1.419–2.906)

0.0001

þ

EpCAM expression, by intrinsic subtype
Luminal A

1.404 (0.771–2.557)

0.2666

Luminal B (HER2  )

0.860 (0.660–1.119)

0.2614

Luminal B (HER2 þ )

1.546 (0.928–2.575)

0.0941

HER2 type

0.329 (0.190–0.570)

o0.0001

Basal-like

1.437 (0.938–2.201)

0.0958

Abbreviations: EpCAM ¼ epithelial cell adhesion molecule; BRE ¼ Elsten’s modification of
Bloom and Richardson; CI ¼ confidence interval; HER2 ¼ human epidermal growth factor
receptor 2.

that specific ablation of EpCAM decreases proliferation in the
MDA-MB-231 cell line but also demonstrated that specific ablation
of EpCAM results in an almost four-fold increase in proliferation
in the SKBR3 cell line, consistent with the IHC analyses.

DISCUSSION

EpCAM is commonly expressed in breast cancer, and EpCAM
expression in primary breast cancers has been widely reported to
be associated with poor prognosis. However, breast cancer is a
heterogeneous disease, and the impact of EpCAM expression on
prognosis in the breast cancer intrinsic subtypes remains to be
investigated. Here, we studied EpCAM expression in a large cohort
of primary breast cancers, with a particular focus on defining the
potential associations between EpCAM expression and the breast
cancer intrinsic subtypes, as defined by the most recent St. Gallen
Consensus Conference (Goldhirsch et al, 2011). Of note, we
www.bjcancer.com | DOI:10.1038/bjc.2013.80

demonstrate for the first time that EpCAM expression varies
significantly between the intrinsic subtypes of breast cancer,
ranging from 22.5% in luminal A to 73.0% in the HER2 subtype.
We have also made the surprising observation that the impact of
EpCAM expression on prognosis in breast cancer is dependent on
intrinsic subtype. In the basal-like and luminal B HER2 þ subtypes,
EpCAM expression is associated with an unfavourable prognosis;
in the HER2 subtype, EpCAM expression is associated with a
favourable prognosis.
Our study confirms the results of previous studies demonstrating that EpCAM expression is associated with tumour size, lymph
node involvement, tumour grade, and prognosis in breast cancer
(Tandon et al, 1990; Schmidt et al, 2008; Spizzo et al, 2011;
Agboola et al, 2011). In addition, we observed that EpCAM
expression is inversely associated with expression of ER
(Po0.0001) and positively associated with HER2 expression
(P ¼ 0.0298), findings that have been previously reported by others
(Spizzo et al, 2002; Schmidt et al, 2008; Agboola et al, 2011).
Although multiple studies have suggested that EpCAM expression
is an independent predictor of disease-free survival and OS (Spizzo
et al, 2002; Schmidt et al, 2008; Agboola et al, 2011), we did not
observe this finding in our collective (P ¼ 0.7824 in multivariate
analysis). This may be related to the strong association we observed
between EpCAM expression and traditional predictors of prognosis in breast cancer, such as tumour size, lymph node
involvement, tumour grade, ER status, HER2 status, intrinsic
subtype, and Ki67 labelling index.
This study is the first to evaluate the association between
EpCAM expression and prognosis in the intrinsic subtypes of
breast cancer. To do this, we used well-recognised criteria for
approximating the intrinsic subtypes using immunohistochemical
criteria (ER status, PR status, HER2, Ki67 labelling index). Because
of the large sample size (n ¼ 1365 cases), we had adequate power to
meaningfully evaluate potential associations between EpCAM
expression and prognosis in the breast cancer intrinsic subtypes,
demonstrating a surprising differential impact on prognosis
between the basal-like, luminal B HER2 þ , and HER2 subtypes.
Recently, Agboola et al (2011) investigated the impact of EpCAM
expression on prognosis in a cohort of 726 primary breast cancer
cases. They observed that EpCAM expression is associated with
tumour size and tumour grade and is an independent predictor of
disease-free and OS. They also evaluated the potential association
between EpCAM expression and other biomarkers, including ER,
HER2, p53, CK5/6, and CK14. Of note, they defined basal-like
breast cancer as CK5/6 and/or CK14-positive and demonstrated
that EpCAM expression is an independent predictor of poor
prognosis in basal-like breast cancer. Although Agboola et al
(2011) use a different criteria to define basal-like breast cancer,
their results are consistent with the results reported here,
confirming the importance of EpCAM expression in this intrinsic
subtype. EpCAM-targeted therapies may be particularly appropriate in this subtype, because EpCAM is expressed in the majority
of basal-like breast cancers and treatment options are otherwise
limited for patients with basal-like breast cancer.
One limitation of our study is that we defined breast cancer
intrinsic subtype using the St. Gallen Consensus Conference
criteria. These criteria provide only an approximation of intrinsic
subtype. For instance, not all triple-negative breast cancers
identified by immunohistochemistry correspond to the intrinsic
basal-like subtype. Although there is an approximately 80% overlap
between triple-negative and intrinsic basal-like subtype, triplenegative cancers also include special histological subtypes, such as
medullary and adenoid cystic carcinoma with a much lower risk of
recurrence (Goldhirsch et al, 2011; Penault-Llorca and Viale,
2012). Thus, using the triple-negative phenotype as an approximation for basal-like breast cancer may underestimate the impact of
EpCAM on this intrinsic subtype.
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translocation of the intracellular portion (Maetzel et al, 2009).
Although we believe that expression of extracellular EpCAM is a
surrogate for EpCAM-dependent signalling, staining with an
antibody to the intracellular portion may provide better insight
into the extent of EpCAM-dependent signalling. Further studies
with a particular emphasis on defining EpCAM signalling may
provide additional insights into the relationship between EpCAM
expression and breast cancer biology.
In summary, we demonstrate that EpCAM expression is
variably expressed in the breast cancer intrinsic subtypes and is
differentially associated with OS in the luminal B HER2 þ , HER2,
and basal-like intrinsic subtypes. This result is consistent with the
hypothesis that the impact of EpCAM expression on cancer
biology is context-dependent and has important implications for
the rational development of novel therapeutics targeting EpCAM
currently under clinical investigation.
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Figure 3. Specific ablation of EpCAM results in increased SKBR3
breast cancer cell viability. (A) EpCAM-shRNA specifically ablates
EpCAM protein levels in MCF-10A, MDA-MB-231, and SKBR3 cells
72 h post infection relative to shGFP control vector. (B) Crystal violetstained plates depicting cell growth differences in MCF10A, MDA-MB231, and SKBR3 cells 14 days post infection. Plates representative of
three independent experiments. (C) Crystal violet growth assay used to
quantify the growth differences between the breast cancer cell lines.
A full color version of this figure is available at the British Journal of
Cancer online.

In this study, we demonstrate, for the first time, that EpCAM is
highly expressed in the HER2 subtype (73.0%). Surprisingly,
EpCAM expression in the HER2 subtype was associated with a
significantly improved OS (P ¼ 0.0004). Consistent with these
findings were the results of in vitro studies, where downregulation
of EpCAM with shRNA led to increased viability and cell growth in
the SKBR3 breast cancer cell line. This cell line corresponds to the
HER2 subtype (ER- and PR  , HER2 þ ), and its increased viability
after specific ablation of EpCAM supports our finding that
EpCAM is associated with favourable prognosis in this breast
cancer subtype. The reason for this differential association with
survival in the HER2 subtype is not known to date. Of note, a study
by Spizzo et al (2002) suggests that concurrent EpCAM and HER2
expression may be associated with an additive negative impact on
disease-related OS. In their study, however, the HER2 þ cases were
evaluated as a single group. The current taxonomy of breast cancer
suggests that HER2 þ cases should be divided into two subtypes,
the luminal B HER2 þ subtype (ER þ and/or PR þ , HER2 þ )
and the HER2 subtype (ER  and PR  , HER2 þ ). In addition,
Spizzo et al (2002) observed simultaneous expression of HER2 and
EpCAM in a much smaller number of cases (13.2% vs 54.3% in
our study). However, our study contains significantly more
patient samples, and for this reason, our observations might have
more power in this regard. Our data clearly suggest that EpCAM
expression in the HER2 subtype is associated with a favourable
prognosis. Therefore, targeting EpCAM in this group of
patients should be performed with caution, particularly if the
therapy is aimed at abrogating EpCAM-dependent signalling
pathways.
A second limitation of this study is that we evaluated expression
of extracellular EpCAM only. Recent evidence suggests that
EpCAM can be cleaved at the cell surface, with nuclear
1486
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